Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes

Yundeok Kim, June Won Cheong, Yeo Kyeoung Kim, Ju In Eom, Hoi Kyung Jeung, Soo Jeong Kim, Dohyu Hwang, Jinseok Kim, Hyeuong Joon Kim, Yoo Hong Min

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2%, P= 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level ( P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients.

Original languageEnglish
Article numbere86933
JournalPloS one
Volume9
Issue number2
DOIs
Publication statusPublished - 2014 Feb 4

Fingerprint

Myelodysplastic Syndromes
Biomarkers
MicroRNAs
microRNA
biomarkers
epigenetics
Serum
therapeutics
Disease-Free Survival
prospective studies
Epigenomics
ROC Curve
Area Under Curve
Multivariate Analysis
Prospective Studies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Kim, Y., Cheong, J. W., Kim, Y. K., Eom, J. I., Jeung, H. K., Kim, S. J., ... Min, Y. H. (2014). Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. PloS one, 9(2), [e86933]. https://doi.org/10.1371/journal.pone.0086933
Kim, Yundeok ; Cheong, June Won ; Kim, Yeo Kyeoung ; Eom, Ju In ; Jeung, Hoi Kyung ; Kim, Soo Jeong ; Hwang, Dohyu ; Kim, Jinseok ; Kim, Hyeuong Joon ; Min, Yoo Hong. / Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. In: PloS one. 2014 ; Vol. 9, No. 2.
@article{8ea5d79f88f642539a221977a49e1d57,
title = "Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes",
abstract = "Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95{\%} confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2{\%}, P= 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level ( P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients.",
author = "Yundeok Kim and Cheong, {June Won} and Kim, {Yeo Kyeoung} and Eom, {Ju In} and Jeung, {Hoi Kyung} and Kim, {Soo Jeong} and Dohyu Hwang and Jinseok Kim and Kim, {Hyeuong Joon} and Min, {Yoo Hong}",
year = "2014",
month = "2",
day = "4",
doi = "10.1371/journal.pone.0086933",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

Kim, Y, Cheong, JW, Kim, YK, Eom, JI, Jeung, HK, Kim, SJ, Hwang, D, Kim, J, Kim, HJ & Min, YH 2014, 'Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes', PloS one, vol. 9, no. 2, e86933. https://doi.org/10.1371/journal.pone.0086933

Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. / Kim, Yundeok; Cheong, June Won; Kim, Yeo Kyeoung; Eom, Ju In; Jeung, Hoi Kyung; Kim, Soo Jeong; Hwang, Dohyu; Kim, Jinseok; Kim, Hyeuong Joon; Min, Yoo Hong.

In: PloS one, Vol. 9, No. 2, e86933, 04.02.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes

AU - Kim, Yundeok

AU - Cheong, June Won

AU - Kim, Yeo Kyeoung

AU - Eom, Ju In

AU - Jeung, Hoi Kyung

AU - Kim, Soo Jeong

AU - Hwang, Dohyu

AU - Kim, Jinseok

AU - Kim, Hyeuong Joon

AU - Min, Yoo Hong

PY - 2014/2/4

Y1 - 2014/2/4

N2 - Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2%, P= 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level ( P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients.

AB - Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2%, P= 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level ( P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients.

UR - http://www.scopus.com/inward/record.url?scp=84895175958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895175958&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0086933

DO - 10.1371/journal.pone.0086933

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e86933

ER -